Synovial Sarcoma - Pipeline Insight, 2024

This “Synovial Sarcoma- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Synovial Sarcoma: Understanding

Synovial Sarcoma: Overview

Synovial sarcoma is a rare type of soft tissue sarcoma that arises primarily around joints, often affecting the arms or legs, though it can occur in other parts of the body as well. Despite its name, it does not originate from synovial tissue (the tissue lining joints) but tends to develop in areas near joints or tendons. The exact cause of synovial sarcoma remains unclear, though genetic mutations, particularly a specific translocation between chromosomes X and 18 (t(X;18)), play a crucial role in its development. This fusion gene, SS18-SSX, drives abnormal cell growth and differentiation, contributing to tumor formation.

Most cases of synovial sarcoma occur in adolescents and young adults, typically between the ages of 15 and 40, with a slight male predominance. The tumor can grow slowly, making it harder to detect until it becomes large or starts affecting surrounding structures like muscles, nerves, or bones. Common symptoms include swelling or a palpable mass near a joint, along with pain or tenderness, though some patients may initially be asymptomatic. As it progresses, synovial sarcoma may limit movement or cause joint dysfunction, depending on its location.

Diagnosis of synovial sarcoma usually involves a combination of imaging studies (such as MRI or CT scans), which help in visualizing the size and extent of the tumor, and a biopsy to confirm the histological characteristics of the sarcoma. Pathologically, synovial sarcoma can appear in two main forms: monophasic (composed of one type of cell, either epithelial or spindle-shaped) or biphasic (a mix of epithelial and spindle cells). Molecular testing is critical to identify the SS18-SSX fusion gene, which aids in distinguishing synovial sarcoma from other soft tissue tumors.

Treatment strategies for synovial sarcoma typically include a combination of surgery, radiation therapy, and chemotherapy. Surgical removal of the tumor with wide margins is the mainstay of treatment, aiming to prevent local recurrence. Radiation therapy is often used either before or after surgery to enhance local control, while chemotherapy may be considered in cases of high-grade or metastatic disease. Despite aggressive treatment, synovial sarcoma has a relatively high risk of recurrence and metastasis, especially to the lungs and lymph nodes, which can complicate management.
"Synovial Sarcoma- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Synovial Sarcoma pipeline landscape is provided which includes the disease overview and Synovial Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Synovial Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Synovial Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Synovial Sarcoma.

Synovial Sarcoma Emerging Drugs Chapters

This segment of the Synovial Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Synovial Sarcoma Emerging Drugs

AL3818: Advenchen Laboratories

Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.

Tazemetostat: Ipsen

Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process.

Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.

OTSA101: OncoTherapy Science

OTSA101 is an anti-FZD10 antibody and has been developed as novel cancer therapy for synovial sarcoma. FZD10, which was identified through genome-wide analysis by the group of Professor Yusuke Nakamura (former Director of Human genome center, Institute of Medical Science,The University of Tokyo) is frequently and highly up regulated in synovial sarcoma but being hardly detectable in normal organs. OTSA101 specifically binds to FZD10 in cancer cells. In addition, radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation in mouse xenograft model. Currently, the drug is in the Phase I stage of its development for the treatment of synovial sarcoma.

Synovial Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Synovial Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Synovial Sarcoma

There are approx. 15+ key companies which are developing the therapies for Synovial Sarcoma. The companies which have their Synovial Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Advenchen Laboratories.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Synovial Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Synovial Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Synovial Sarcoma drugs.

Synovial Sarcoma Report Insights

• Synovial Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Synovial Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Synovial Sarcoma drugs?
• How many Synovial Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Synovial Sarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Synovial Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Synovial Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Advenchen Laboratories
• Ipsen
• OncoTherapy Science
• C4 Therapeutics
• Takara Bio
• BioAtla, Inc.
• Immatics Biotechnologies GmbH
• Sapience Therapeutics
• PharmaMar

Key Products

• AL3818
• Tazemetostat
• OTSA101
• CFT 8634
• TBI-1301
• BA-3011
• IMA402
• ST316
• Lurbinectedin

This product will be delivered within 1-3 business days.